REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study
Launched by JOHNS HOPKINS UNIVERSITY · Nov 3, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The REASSESS study will conduct long-term cognitive, functional, and neuropsychiatric performance assessments to determine if evacuation of spontaneous intracerebral hemorrhage (ICH) reduces the risk of later cognitive decline in the ageing brain. This study will compare rates of cognitive decline under two treatment strategies for intracerebral hemorrhage: the use of minimally invasive surgery with two similar techniques as performed in the MISTIE III and ENRICH trials, and the current standard of care using data from controls in MISTIE III and ENRICH and comparative data from The Ethnic/R...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participants in the study must be survivors enrolled in MISTIE III and ENRICH trials at end of each trial's final follow-up (day 365 in MISTIE III and day 180 in ENRICH). Relatives of known survivors that are found to be deceased since the end of each trial will be interviewed to capture relevant data.
- Exclusion Criteria:
- • None
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Baltimore, Maryland, United States
Stanford, California, United States
San Antonio, Texas, United States
Detroit, Michigan, United States
Albuquerque, New Mexico, United States
Winston Salem, North Carolina, United States
Nashville, Tennessee, United States
Jacksonville, Florida, United States
Philadelphia, Pennsylvania, United States
Louisville, Kentucky, United States
Baltimore, Maryland, United States
Chicago, Illinois, United States
New Haven, Connecticut, United States
La Jolla, California, United States
Cincinnati, Ohio, United States
Fairway, Kansas, United States
Birmingham, Alabama, United States
Minneapolis, Minnesota, United States
Ann Arbor, Michigan, United States
Sacramento, California, United States
Chicago, Illinois, United States
Saint Louis, Missouri, United States
Piscataway, New Jersey, United States
Bronx, New York, United States
Houston, Texas, United States
Fairfax, Virginia, United States
Patients applied
Trial Officials
Wendy Ziai, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials